Jason Raleigh Nunn, Director at Hyperion Therapeutics, holds 3.12M shares in Zenas BioPharma, Inc. (Ticker: ZBIO), holds 0.00 shares in Regulus (Ticker: RGLS), holds 4.27K shares in Trevena (Ticker: TRVN). Most recently, Jason Raleigh Nunn Bought ― shares of Zenas BioPharma, Inc. on Oct 14, 2025 for an estimated value of $1.20M.
Jason Raleigh Nunn latest transaction was an Informative Buy of $1.20M.
What was Jason Raleigh Nunn's most profitable transaction?
Jason Raleigh Nunn’s most profitable transaction was an Informative Buy of ZBIO stock on September 16, 2024. The return on the trade was 1.50%.
What is Jason Raleigh Nunn's role in Hyperion Therapeutics?
Jason Raleigh Nunn's role in Hyperion Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.